Both the parties will select between five and ten projects, decided on by a committee of UCB and Oxford University representatives, InPharm reported.
UCB’s immunology research center currently focuses on research for conditions such as rheumatoid arthritis, lupus, inflammatory bowel disease and osteoporosis.
Oxford University medicine regius professor John Bell said the partnerships between industry and academia will have an increasingly prominent role to play in the development of new drugs, therapies and medical technologies.
UCB chief executive Roch Doliveux said Oxford University’s academic research will dovetail with UCB’s work on antibodies.